MOSAR: MoMa Signature During Granulomatosis
Study Details
Study Description
Brief Summary
Sarcoidosis is a systemic inflammatory disease characterized by unspecific granuloma formation. Our hypothesis is that granuloma formation and maintenance mainly relies on the overactivation of monocytes (Mo) and macrophages (Ma). To this end, the study aims (i) to define MoMa systemic signature in sarcoidosis, (ii) to characterize this signature in situ on tissue samples, and (iii) to identify causative factors that participate to the MoMa chronic overactivation. Thus, a cohort of sarcoidosis patients will be compared with tuberculosis patients. The MoMa systemic signature will be defined on whole blood (TruCulture model) and then in situ through different methods (multi-parameter spectral flow cytometry, RNA-seq, Luminex, imaging mass cytometry). The epigenome of monocytes will be studied thanks to CUT&Tag. The MoMa systemic signature will be defined ex vivo at different time points during the course of the disease with phenotypic, transcriptomic, cytokine and functional approaches. The previously identified signature will be studied in situ and completed by the characterization of granuloma architecture and microenvironmental interactions, which could be modulated by epigenetic modifications. Hence, the epigenome of monocytes will be analyzed in two groups (sarcoidosis and tuberculosis). These results would allow to better understand sarcoidosis physiopathology and, in fine, may raise new therapeutic strategies. Finally, the study could challenge the dogma on innate immunity/auto-inflammation versus adaptive immunity/auto-immunity/memory.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
"Sarcoidosis is an inflammatory disease characterized by the presence of coalescing, tightly clustered, non-necrotizing granulomas. The diagnosis is based on three major criteria: a compatible clinical presentation, the presence of non-necrotizing granulomatous inflammation, and the exclusion of alternative granulomatous diseases. A wide range of clinical phenotypes are observed depending on the location of the granulomatous lesions which can affect any organ, with the lungs being the most affected site. Sarcoidosis shares many similarities with tuberculosis, in which granuloma formation is triggered by Mycobacterium tuberculosis (M. tb). These phenotypic similarities between the two diseases present many challenges for diagnosis, clinical management and therapy.
Our understanding of the factors that contribute to sarcoidosis development, granuloma formation and maintenance remains limited. Part of this challenge is that granuloma development may involve both environmental and genetic factors, which contribute to the recruitment of immune cells to form the granuloma. Immune cells involved in the granuloma include (1) CD4 Th1 and Th17 T cells and their associated cytokines (e.g, IFNγ, TNFα, IL-17, IL-2); and (2) monocytes (Mo) and macrophages (Ma) including proinflammatory M1 and pro-fibrosis M2 types. However, the specific factors that contribute to granuloma maintenance and evolution remain to be identified. Among them, we can hypothesized that trained immunity, persistence of the antigen, or the microenvironment are involved in this chronic dysregulated immune response. Such an improved understanding of the pathophysiology of the disease may allow development of new treatments, as currently corticosteroids remain the mainstay of therapy.
Our main hypothesis is that granuloma formation and maintenance mainly relies on the overactivation of monocytes (Mo) and macrophages (Ma). To this end, the study aims (i) to define MoMa systemic signature in sarcoidosis, (ii) to characterize this signature in situ on tissue samples, and (iii) to identify causative factors that participate to the MoMa chronic overactivation. Thus, a cohort of sarcoidosis patients will be compared with tuberculosis patients. The MoMa systemic signature will be defined on whole blood (TruCulture model) and then in situ through different methods (multi-parameter spectral flow cytometry, RNA-seq, Luminex, imaging mass cytometry). The epigenome of monocytes will be studied thanks to CUT&Tag. The MoMa systemic signature will be defined ex vivo at different time points (M0, M6 and M12) during the course of the disease with phenotypic, transcriptomic, cytokine and functional approaches. The previously identified signature will be studied in situ and completed by the characterization of granuloma architecture and microenvironmental interactions, which could be modulated by epigenetic modifications. Hence, the epigenome of monocytes will be analyzed in two groups (sarcoidosis and tuberculosis). These results would allow to better understand sarcoidosis physiopathology and, in fine, may raise new therapeutic strategies. Finally, the study could challenge the dogma on innate immunity/auto-inflammation versus adaptive immunity/auto-immunity/memory."
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Sarcoidosis patients diagnosed with sarcoidosis |
Other: blood sample
blood sample collection
|
| Tuberculosis patients diagnosed with tuberculosis |
Other: blood sample
blood sample collection
|
Outcome Measures
Primary Outcome Measures
- macrophage activation in sarcoidosis measured by epigenomic [up to 12 months of follow-up.]
performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood
- monocyte activation in sarcoidosis measured by epigenomic [up to 12 months of follow-up.]
performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood
- macrophage activation in sarcoidosis measured by flow cytometry [up to 12 months of follow-up.]
performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood
- monocyte activation in sarcoidosis measured by flow cytometry [up to 12 months of follow-up.]
performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood
- monocyte activation in sarcoidosis measured by transcriptomic [up to 12 months of follow-up.]
performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood
- macrophage activation in sarcoidosis measured by transcriptomic [up to 12 months of follow-up.]
performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood
- macrophage activation in sarcoidosis measured by cytokine measurement [up to 12 months of follow-up.]
performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood
- monocyte activation in sarcoidosis measured by cytokine measurement [up to 12 months of follow-up.]
performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood
Secondary Outcome Measures
- monocyte activation in tuberculosis measured by epigenomic [up to 12 months of follow-up.]
- Identification of a pathogen that triggers sarcoidosis development by metagenomic study [Samples collected before treatment/at diagnosis]
- identification of epigenetic modifications of monocytes by CUT&Tag method [12 months of follow-up.]
CUT&Tag-sequencing, also known as cleavage under targets and tagmentation, is a method used to analyze protein interactions with DNA
- Identification of a diagnostic test to discriminate sarcoidosis and tuberculosis [Samples collected before treatment/at diagnosis]
measurement of IFNγ secretion by whole blood in response to stimulation by tuberculosis antigen
Eligibility Criteria
Criteria
Inclusion criteria:
-
Male and female > 18 years old
-
Diagnosis of sarcoidosis and of tuberculosis
-
Affiliated to medical insurance
Exclusion criteria:
-
HIV infection
-
pregnant or breastfeeding woman
-
Patient under legal protection, guardianship or curators
-
Absence of signed consent"
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hôpital Bichat | Paris | France | 75018 |
Sponsors and Collaborators
- Assistance Publique - Hôpitaux de Paris
Investigators
- Principal Investigator: Karim SACRE, MD-PhD, PU-PH, Assistance Publique - Hôpitaux de Paris
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- APHP230273
- 2022-A02637-36